Cargando…
S224: HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY
Autores principales: | Jacobs, Ryan, Nair, Ranjit, Cho, Seok-Goo, Devata, Sumana, Gaballa, Sameh, Yoon, Dok Hyun, Stevens, Don, Kim, Jin Seok, Shah, Nirav N, Brennan, Denise Marie, Law, Jason, Lesley, Robin, Chen, Rob, Forcina, Alessandra, Buelow, Ben, Hou, Jing-Zhou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428429/ http://dx.doi.org/10.1097/01.HS9.0000967808.60614.fc |
Ejemplares similares
-
TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL
por: Malik-Chaudhry, Harbani K., et al.
Publicado: (2021) -
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity
por: Ugamraj, Harshad S., et al.
Publicado: (2022) -
Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma
por: Foureau, David M., et al.
Publicado: (2020) -
Interim Report for Input to WP2.2.4: Milestone MS22
por: Burrows, P., et al.
Publicado: (2013) -
SUN-486 Unusual Presentation of Metastatic Follicular Thyroid Cancer
por: Proudan, Nikoletta, et al.
Publicado: (2020)